Centiva Capital LP Purchases Shares of 10,727 Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Centiva Capital LP bought a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 10,727 shares of the specialty pharmaceutical company's stock, valued at approximately $307,000.

A number of other institutional investors and hedge funds have also bought and sold shares of COLL. New Age Alpha Advisors LLC purchased a new position in shares of Collegium Pharmaceutical during the fourth quarter worth $40,000. KBC Group NV grew its holdings in shares of Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock worth $67,000 after buying an additional 982 shares during the last quarter. Nisa Investment Advisors LLC increased its position in Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after purchasing an additional 316 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Collegium Pharmaceutical by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock worth $196,000 after purchasing an additional 642 shares during the period. Finally, Aigen Investment Management LP acquired a new stake in shares of Collegium Pharmaceutical in the 4th quarter worth approximately $230,000.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL traded up $0.89 during midday trading on Friday, hitting $30.23. The stock had a trading volume of 430,854 shares, compared to its average volume of 429,690. The company's 50-day moving average price is $28.12 and its 200-day moving average price is $29.82. The company has a market capitalization of $971.35 million, a P/E ratio of 13.03 and a beta of 0.63. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a fifty-two week low of $23.23 and a fifty-two week high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.50 by ($0.01). Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company had revenue of $177.76 million for the quarter, compared to the consensus estimate of $174.96 million. During the same period in the prior year, the company earned $1.45 earnings per share. The firm's revenue was up 22.7% compared to the same quarter last year. As a group, equities research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Needham & Company LLC restated a "buy" rating and set a $46.00 price objective on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. StockNews.com cut Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 19th. Piper Sandler reaffirmed a "neutral" rating and issued a $37.00 price target (up previously from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. Finally, HC Wainwright reiterated a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $43.80.

Insider Activity at Collegium Pharmaceutical

In other news, EVP Shirley R. Kuhlmann sold 40,000 shares of the firm's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the sale, the executive vice president now owns 154,204 shares of the company's stock, valued at $4,330,048.32. This trade represents a 20.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Colleen Tupper sold 1,949 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $30.00, for a total transaction of $58,470.00. Following the completion of the transaction, the chief financial officer now owns 177,195 shares in the company, valued at $5,315,850. This trade represents a 1.09% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 81,693 shares of company stock valued at $2,334,994. Corporate insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.